atexakin alfa
Phase 2- Indications
- Peripheral diabetic neuropathy
Company intelligence / Profile preview
PX'Therapeutics was a leading French CRO/CDMO specializing in the development, engineering, process development, and GMP bioproduction of recombinant proteins—including monoclonal antibodies—for research through clinical use. It supported over 160 clients globally with expertise spanning early-stage research to clinical-grade manufacturing. In July 2019, it merged with Promise Advanced Proteomics under the Aguettant group to form Promise Proteomics. Notable projects included production of atexakin alfa for Relief Therapeutics targeting peripheral diabetic neuropathy and R&D programs such as OM-RCA–001 for kidney neoplasms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PX'Therapeutics.